INTRODUCTION
The therapeutic protein market grew by 14% in 2001 and is forecast to achieve
sales of over $57bn by 2010. Growth to date has been dominated by sales of
erythropoietins and insulins, while future growth will reflect the increasing
significance of monoclonal antibodies and therapeutic vaccines. However, there
are a number of critical issues that companies must overcome to be successful,
notably the threat of biogenerics and the imminent shortfall in biologics
manufacturing capacity.
SCOPE OF THIS REPORT
- Analysis of global and 7 country (US, Japan, France, Germany, Italy,
Spain, UK) product and class sales across 13 therapeutic protein classes
- In-depth evaluation of the commercial potential of the therapeutic protein
R&D pipeline
- Forecast year-on-year sales for all major products and classes to 2010
- Recommendations for managing the emerging threat from biogenerics,
including a timeline of impact, key companies involved and products most at
risk
- Analysis of the forthcoming shortfall in manufacturing capacity and its
implications for future market growth
REPORT HIGHLIGHTS
The strategies adopted by Pfizer and Aventis to gain regulatory approval and
overcome the safety issues facing the first non-injectable insulin Exubera, will
set a precedent for other companies with earlier stage inhalable and oral
insulins.
The intensive, high volume manufacturing process for monoclonal antibodies
has resulted in drugs having to command premium prices, limiting their market
penetration. However, with over 35 products in phase II development, competition
within the monoclonal antibody class will strengthen as more products make it
through to market by 2010.
Over $13.5bn of the $27bn therapeutic proteins market in 2001 will be exposed
to generic competition by the end of 2005.
KEY REASONS TO BUY THIS REPORT
- Optimize penetration with comprehensive knowledge of the sales
performance, growth drivers and country-specific factors surrounding
competing proteins
- Identify key pipeline products for in-licensing opportunities and areas of
unmet need
- Maximize your product's potential by implementing optimal biogeneric
defense strategies
- Target resources more effectively to ensure that your required
manufacturing capacity is available
View Cart
